Anti-PGAP3 antibody (300-350) {FITC} (STJ502451)

SKU:
STJ502451-100

Shipping:
Free Shipping
Current Stock:
Host: Rabbit
Applications: DB/ELISA/IP/WB
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-PGAP3 (300-350) is suitable for use in Dot Blot, ELISA, Immunoprecipitation and Western Blot research applications.
Clonality: Polyclonal
Conjugation: FITC
Isotype: IgG
Purification: Affinity Purified
Concentration: 0.50-0.75 µg/µl
Dilution Range: WB: 1:500-1:1, 000
DB: 1:50, 000
ELISA: 1:50, 000
IP: 1:150
Storage Instruction: Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Gene Symbol: PGAP3
Gene ID: 93210
Uniprot ID: PGAP3_HUMAN
Immunogen Region: 300-350
Immunogen: Synthetic Peptide taken within amino acid region 300-350 on human PGAP3 protein.
Tissue Specificity Ubiquitously expressed, with highest levels in thyroid and placenta.
Function Involved in the lipid remodeling steps of GPI-anchor maturation. Lipid remodeling steps consist in the generation of 2 saturated fatty chains at the sn-2 position of GPI-anchors proteins. Required for phospholipase A2 activity that removes an acyl-chain at the sn-2 position of GPI-anchors during the remodeling of GPI.
Protein Name Post-Gpi Attachment To Proteins Factor 3
Cos16 Homolog
Hcos16
Gene Coamplified With Erbb2 Protein
Per1-Like Domain-Containing Protein 1
Cellular Localisation Golgi Apparatus Membrane
Multi-Pass Membrane Protein
Endoplasmic Reticulum Membrane
Mainly Localizes To Golgi Apparatus
Alternative Antibody Names Anti-Post-Gpi Attachment To Proteins Factor 3 antibody
Anti-Cos16 Homolog antibody
Anti-Hcos16 antibody
Anti-Gene Coamplified With Erbb2 Protein antibody
Anti-Per1-Like Domain-Containing Protein 1 antibody
Anti-PGAP3 antibody
Anti-CAB2 antibody
Anti-PERLD1 antibody
Anti-UNQ546 antibody
Anti-PRO1100 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance